Over the last 10 – 20 years, medical science has made remarkable discoveries about central nervous system (CNS) disorders. This knowledge has led to advances in treatments and new therapies for diseases ranging from multiple sclerosis to depression.
According to the Schizophrenia Society of Canada, schizophrenia affects one in every 100 individuals. In the last decade, AstraZeneca has developed a treatment that provides significant improvement for schizophrenia patients.
With decades of experience in the discovery and delivery of neurological medicines, we are committed to alleviating the devastating impact of pain. Our vision today is to maintain our leadership in anaesthesia with our innovative therapies that continue to meet medical needs for effective analgesia. Currently, we are world leaders in the field of anaesthesia, with a leading general anaesthetic, as well as a complete range of local anaesthetics in our product portfolio.
The Neuroscience group also has an exciting pipeline which includes products for stroke, Alzheimer’s disease, depression and anxiety, overactive bladder, and acute and chronic pain.